Arcoma (ARCOMA) Q3 2025 earnings summary

Executive summary

• Strong demand in the US drove growth, while Europe experienced a hesitant market, leading to a decline in sales in that region.

• Operational improvements and cost efficiency maintained profitability despite lower sales and negative currency effects.

• Several new product enhancements were launched, and three new distributors were added in Europe during 2025.

Financial highlights

• Q3 net sales were 29,887 KSEK, down from 31,886 KSEK year-over-year.

• EBITDA for Q3 was 3,861 KSEK (13% margin), compared to 4,325 KSEK (13%) last year.

• Pre-tax profit for Q3 was 1,991 KSEK, down from 2,303 KSEK; EPS was 0.11 SEK (0.14 SEK last year).

• Nine-month net sales totaled 96,140 KSEK, down from 120,005 KSEK; EBITDA was 10,221 KSEK (16,573 KSEK last year).

• Cash flow for the quarter was 9,098 KSEK, supported by a directed share issue.

Outlook and guidance

• The company remains optimistic for the coming quarters, focusing on profitability and selective investments.

• Ongoing efforts to expand through acquisitions and product innovation are expected to support future growth.